BSE Live
Jan 09, 16:01Prev. Close
5796.65
Open Price
5758.20
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Jan 09, 15:55Prev. Close
5793.00
Open Price
5775.50
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
5799.00 (10)
| Balance Sheet of Alkem Laboratories (in Rs. Cr.) | Mar 15 | Mar 14 | |
| 12 mths | 12 mths | ||
| EQUITIES AND LIABILITIES | |||
| SHAREHOLDER'S FUNDS | |||
| Equity Share Capital | 23.91 | 11.96 | |
| Total Share Capital | 23.91 | 11.96 | |
| Reserves and Surplus | 2,975.14 | 2,643.14 | |
| Total Reserves and Surplus | 2,975.14 | 2,643.14 | |
| Total Shareholders Funds | 2,999.05 | 2,655.10 | |
| Minority Interest | 85.65 | 0.00 | |
| NON-CURRENT LIABILITIES | |||
| Long Term Borrowings | 33.43 | 232.25 | |
| Deferred Tax Liabilities [Net] | 96.35 | 60.91 | |
| Other Long Term Liabilities | 5.14 | 7.79 | |
| Long Term Provisions | 66.58 | 27.78 | |
| Total Non-Current Liabilities | 201.50 | 328.73 | |
| CURRENT LIABILITIES | |||
| Short Term Borrowings | 1,128.57 | 845.22 | |
| Trade Payables | 461.92 | 305.73 | |
| Other Current Liabilities | 331.07 | 187.91 | |
| Short Term Provisions | 84.42 | 25.01 | |
| Total Current Liabilities | 2,005.98 | 1,363.87 | |
| Total Capital And Liabilities | 5,295.76 | 4,347.70 | |
| ASSETS | |||
| NON-CURRENT ASSETS | |||
| Tangible Assets | 972.65 | 877.19 | |
| Intangible Assets | 59.59 | 32.39 | |
| Capital Work-In-Progress | 110.69 | 70.68 | |
| Fixed Assets | 1,142.93 | 980.26 | |
| Non-Current Investments | 419.73 | 338.23 | |
| Deferred Tax Assets [Net] | 4.48 | 5.11 | |
| Long Term Loans And Advances | 542.17 | 438.48 | |
| Other Non-Current Assets | 506.30 | 782.70 | |
| Total Non-Current Assets | 2,957.71 | 2,735.21 | |
| CURRENT ASSETS | |||
| Current Investments | 61.05 | 249.73 | |
| Inventories | 784.23 | 620.33 | |
| Trade Receivables | 527.08 | 373.46 | |
| Cash And Cash Equivalents | 790.76 | 206.29 | |
| Short Term Loans And Advances | 129.63 | 129.92 | |
| OtherCurrentAssets | 45.30 | 32.76 | |
| Total Current Assets | 2,338.05 | 1,612.49 | |
| Total Assets | 5,295.76 | 4,347.70 | |
| OTHER ADDITIONAL INFORMATION | |||
| CONTINGENT LIABILITIES, COMMITMENTS | |||
| Contingent Liabilities | 309.71 | 193.85 | |
| BONUS DETAILS | |||
| Bonus Equity Share Capital | 11.96 | 5.98 | |
| NON-CURRENT INVESTMENTS | |||
| Non-Current Investments Quoted Market Value | 164.12 | 59.76 | |
| Non-Current Investments Unquoted Book Value | 261.97 | 278.47 | |
| CURRENT INVESTMENTS | |||
| Current Investments Quoted Market Value | 10.22 | 253.45 | |
| Current Investments Unquoted Book Value | 51.76 | 7.34 |
09.01.2026
04.12.2025
Alkem Lab Consolidated September 2025 Net Sales at Rs 4,000.99 crore, up 17.17% Y-o-Y
24.11.2025
Alkem Lab Standalone September 2025 Net Sales at Rs 2,542.03 crore, down 11.49% Y-o-Y
18.11.2025
04.12.2025
Alkem Lab Consolidated September 2025 Net Sales at Rs 4,000.99 crore, up 17.17% Y-o-Y
24.11.2025
Alkem Lab Standalone September 2025 Net Sales at Rs 2,542.03 crore, down 11.49% Y-o-Y
10.09.2025
Alkem Lab Standalone June 2025 Net Sales at Rs 2,372.17 crore, down 5.12% Y-o-Y
12.08.2025
Q1 Results impact: Alkem Labs, PN Gadgil shares rally up to 10% on strong earnings, Granules up 4%
12.07.2023
Alkem Laboratories Q1 PAT seen up 135.1% YoY to Rs 299.7 cr: Nirmal Bang
17.10.2018
Alkem Labs Q2 PAT may dip 30.2% YoY to Rs. 220 cr: HDFC Securities
20.04.2018
Alkem Labs Q4 PAT may dip 1.5% YoY to Rs. 130 cr: HDFC Securities
12.04.2018
Pharma Q4 earnings preview: Tough quarter; US pricing pressure, domestic sales recovery hold key